Caribou Biosciences cut to market perform from outperform; price target lowered to $1 from $4
CRBU•Leerink Partners cut its rating on Caribou Biosciences to market perform from outperform and lowered its price target to $1 from $4.
Related News
Australia, NZ dollars find some support, trend still down
TLT•
Digital Realty announces pricing of €1 billion of guaranteed notes due 2036
DLR•
Pembina Pipeline Corporation: JP Morgan raises target price to C$75 from C$74
PBA•
Marvell Technology: StoneX raises target price to $375 from $275
MRVL•
GIC Private sells about $710.71 million of Medline common shares
MDLN•